Evidence map›Paper›PMID 35783262›Full record

ArticleFrontiers in genetics2022

Increased

Guoshun Zhang, Hua Shang, Bin Liu, Guikai Wu, Diyang Wu, Liuqing Wang, Shengnan Li, Zhiyuan Wang, Suying Wang, Juxiang Yuan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Guoshun ZhangSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Hua ShangBlood Purification Department of Tangshan Infectious Disease Hospital, Tangshan, China.
Bin LiuDepartment of Gastroenterology, Chaisang District People's Hospital, Jiujiang, China.
Guikai WuDepartment of Gastroenterology, Tangshan Workers' Hospital, Tangshan, China.
Diyang WuDepartment of Gastroenterology, Tangshan Workers' Hospital, Tangshan, China.
Liuqing WangDepartment of Gastroenterology, Hongci Hospital, Tangshan, China.
Shengnan LiDepartment of Gastroenterology, Affiliated Hospital of North China University of Technology, Tangshan, China.
Zhiyuan WangDepartment of Gastroenterology, Affiliated Hospital of North China University of Technology, Tangshan, China.
Suying WangDepartment of Gastroenterology, Affiliated Hospital of North China University of Technology, Tangshan, China.
Juxiang YuanSchool of Public Health, North China University of Science and Technology, Tangshan, China.
North China University of Technology · CNLiaoning Provincial People's Hospital · CNNorth China University of Science and Technology · CNTangshan People's Hospital · CNJiujiang First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is one of the most common malignant tumors in the digestive system. Traditional diagnosis and treatment methods have not significantly improved the overall survival of patients. In this study, we explored the value of

Indexed as

ATP2A1CRCsimmune infiltrationoncogeneprognosis

Identifiers

PMID35783262
PMCPMC9243465
OpenAlexW4282974139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.